Vascular endothelial dysfunction and pharmacological treatment.
Level 5 - mechanism / opinion, no new human data
Narrative review detailing physiological mechanisms and drug classes without systematic review methodology or primary data
PubMed 26635921 · doi:10.4330/wjc.v7.i11.719
What was done
This is a narrative review detailing the physiological roles of the endothelium, risk factors promoting endothelial dysfunction, underlying molecular mechanisms (particularly reduced nitric oxide bioavailability and oxidative stress), and currently used or investigational pharmacological interventions targeting these pathways.
What was found
The abstract reports no quantitative findings, effect sizes, or study counts. It qualitatively summarizes that risk factors (such as hypertension, hyperglycemia, hypercholesterolemia, smoking, and aging) drive endothelial dysfunction via reactive oxygen/nitrogen species, inflammation, and loss of nitric oxide bioavailability. It notes that diverse drug classes—including ACE inhibitors, angiotensin receptor blockers, statins, beta-blockers, calcium channel blockers, eNOS enhancers, and PDE5 inhibitors—exert endothelial protective effects tailored to specific underlying mechanisms.
Why it matters
It outlines how diverse cardiovascular medications can be conceptually matched to specific cellular mechanisms of endothelial injury rather than used as interchangeable therapies.
Limits
The publication is a non-systematic narrative review providing no primary experimental data, meta-analytic pooling, or quality appraisal of the cited preclinical and clinical literature.
Cited by
- supports Nitric oxide facilitates arterial vasodilation, decreases with aging, and is significantly depleted by high glucose levels in the bloodstream.